$9.74
7.37% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Nurix Therapeutics Inc Stock price

$10.51
-3.68 25.93% 1M
-11.16 51.50% 6M
-8.33 44.21% YTD
-4.08 27.96% 1Y
-3.99 27.52% 3Y
-8.50 44.71% 5Y
-8.50 44.71% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.87 7.65%
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Key metrics

Market capitalization $797.57m
Enterprise Value $216.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.96
P/S ratio (TTM) P/S ratio 14.62
P/B ratio (TTM) P/B ratio 1.51
Revenue growth (TTM) Revenue growth -29.15%
Revenue (TTM) Revenue $54.55m
EBIT (operating result TTM) EBIT $-213.03m
Free Cash Flow (TTM) Free Cash Flow $-181.86m
Cash position $609.58m
EPS (TTM) EPS $-2.89
P/E forward negative
P/S forward 13.66
EV/Sales forward 3.70
Short interest 17.12%
Show more

Is Nurix Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Nurix Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Nurix Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Nov '24
+/-
%
55 55
29% 29%
100%
- Direct Costs 16 16
20% 20%
30%
38 38
40% 40%
70%
- Selling and Administrative Expenses 22 22
3% 3%
41%
- Research and Development Expense 212 212
17% 17%
389%
-197 -197
39% 39%
-360%
- Depreciation and Amortization 16 16
20% 20%
30%
EBIT (Operating Income) EBIT -213 -213
37% 37%
-391%
Net Profit -194 -194
34% 34%
-355%

In millions USD.

Don't miss a Thing! We will send you all news about Nurix Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nurix Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 mil...
Neutral
GlobeNewsWire
10 days ago
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentatio...
Neutral
GlobeNewsWire
18 days ago
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmace...
More Nurix Therapeutics Inc News

Company Profile

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Head office United States
CEO Arthur Sands
Employees 286
Founded 2009
Website www.nurixtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today